rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Kate Haviland

Director

Company insider

Files Form 4 as: Director, Fulcrum Therapeutics; Director, Bicara Therapeutics; Director, Avalyn Pharma; Chief Executive Officer, Blueprint Medicines.

Every Form 4 they filed

In numbers

Trades disclosed
176
Buys
1
Sells
32
Bought
$48K
Sold
$13.6M
Companies
4
Companies where not an officer
3
First trade
1 Feb 2016
Last trade
30 Jun 2026
Last filed
2 Jul 2026

Companies traded

Where they are an officer
Blueprint MedicinesDirector, Officer · last 17 Jul 20251 buy · 32 sells
Everywhere else they filed: board seats, 10% stakes, other companies
FULC Fulcrum TherapeuticsDirector · Biotechnology · last 30 Jun 20260 buys · 0 sells
BCAX Bicara TherapeuticsDirector · Biotechnology · last 9 Jun 20260 buys · 0 sells
AVLN Avalyn PharmaDirector · Biotechnology · last 29 Apr 20260 buys · 0 sells

Activity over time

1 Nov 2024 – 1 Oct 2026
20Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
30 Jun 2026filed 2 Jul 2026FULC Fulcrum Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—32,000 at $0.00filing
30 Jun 2026filed 2 Jul 2026FULC Fulcrum Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—32,000 at $0.00filing
9 Jun 2026filed 10 Jun 2026BCAX Bicara Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—19,475 at $0.00filing
9 Jun 2026filed 10 Jun 2026BCAX Bicara Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—19,475 at $0.00filing
29 Apr 2026filed 1 May 2026AVLN Avalyn Pharmaoption or derivative · BiotechnologySEC FORM 4 Code A—26,978 at $0.00filing
29 Apr 2026filed 1 May 2026AVLN Avalyn Pharmaoption or derivative · BiotechnologySEC FORM 4 Code A—26,978 at $0.00filing
17 Jul 2025filed 21 Jul 2025Blueprint Medicinesoption or derivativeSEC FORM 4 Code D—2filing
17 Jul 2025filed 21 Jul 2025Blueprint Medicinesoption or derivativeSEC FORM 4 Code D—591filing
17 Jul 2025filed 21 Jul 2025Blueprint Medicinesoption or derivativeSEC FORM 4 Code D—39,000filing
17 Jul 2025filed 21 Jul 2025Blueprint Medicinesoption or derivativeSEC FORM 4 Code D—32,500filing
17 Jul 2025filed 21 Jul 2025Blueprint Medicinesoption or derivativeSEC FORM 4 Code D—28,500filing
17 Jul 2025filed 21 Jul 2025Blueprint Medicinesoption or derivativeSEC FORM 4 Code D—26,125filing
17 Jul 2025filed 21 Jul 2025Blueprint Medicinesoption or derivativeSEC FORM 4 Code D—80,000filing
17 Jul 2025filed 21 Jul 2025Blueprint Medicinesoption or derivativeSEC FORM 4 Code D—80,000filing
17 Jul 2025filed 21 Jul 2025Blueprint Medicinesoption or derivativeSEC FORM 4 Code D—80,000filing
17 Jul 2025filed 21 Jul 2025Blueprint Medicinesoption or derivativeSEC FORM 4 Code D—70,400filing
17 Jul 2025filed 21 Jul 2025Blueprint MedicinesSEC FORM 4 Code A—129,210filing
17 Jul 2025filed 21 Jul 2025Blueprint MedicinesSEC FORM 4 Code D—224,410filing
17 Jul 2025filed 21 Jul 2025Blueprint MedicinesSEC FORM 4 Code U—70,729filing
26 Jun 2025filed 30 Jun 2025FULC Fulcrum Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—36,000 at $0.00filing

News

No headline names them, or the companies they trade most, lately.

Sectors

Not placed33

Buys in green, sells in red, by the company’s sector.

Related people

Nobody else traded the same names lately.